Evaluation of Safety, Tolerance and Pharmacokinetics/Pharmacodynamics of SY-009 Capsules After Single Dose Incremental Oral Administration in Healthy Subjects
Latest Information Update: 04 Nov 2021
At a glance
- Drugs SY 009 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Yabao Pharmaceutical Group
Most Recent Events
- 11 Oct 2019 New trial record